This prospective study will be conducted in high-risk B-ALL patients post-allo-HSCT. We propose to investigate the safety and therapeutic efficacy of blinatumomab plus low-dose DLI maintenance therapy, with the ultimate goal of enhancing long-term survival outcomes.
1) Voluntary participation: The participant or legal guardian fully understands this clinical study, provides informed consent (ICF), and is willing/able to comply with all trial procedures.
>CR1 status
Pre-transplant MRD+ status
Ph-like subtype
1) Drug hypersensitivity/contraindications: Patients with known allergies or contraindications to the investigational drug(s).
Liver: ALT or AST > 2.5 × ULN; Total bilirubin > 2 × ULN
Kidney: Serum creatinine > ULN 8) Investigator judgment: Patients deemed ineligible by investigators (e.g., poor compliance, substance abuse).
Liping Dou
Lead sponsor
Chinese PLA General Hospital
Sponsor institution